ClinicalTrials.gg
CompletedNCT03384823Updated Oct 10, 2018

A Study of EDP-938 in Healthy Subjects

A Phase 1 interventional study of EDP-938 and Placebo in RSV Infection, sponsored by Enanta Pharmaceuticals, Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-10.

Sponsored by Enanta Pharmaceuticals, Inc · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2018, 8 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections — 1 open to participants now, 1 under way, none of them phase 3. EDP-938 · Respiratory Syncytial Virus Infections.

Enrollment
4th of 10
90 · median 81
Started
2017
the only one that year
Phase 1
6 of 10
none open now
Registered
1st of 10
by date
Lead sponsor
10 of 10
Enanta Pharmaceuticals, Inc

Among the 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections, this one is the 4th largest by enrollment, is the only one that started in 2017, is one of 6 in phase 1, and was the 1st registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About EDP-938

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing EDP-938 in Respiratory Syncytial Virus Infections, or all of them as a file.
02

Study summary

This randomized, double-blind, placebo-controlled study will assess the safety, tolerability, and pharmacokinetics of single and multiple orally administered doses of EDP-938 in healthy adult subjects

Read the detailed description

The first phase assesses single ascending doses for EDP-938 (active drug or placebo) in healthy subjects. A "fasted" and "fed" two-part cohort will also assess food effect.

The second phase assesses multiple ascending doses (active drug or placebo) for 7-days in healthy subjects.

Each cohort within each phase will enroll a total of 8 subjects who will be randomized to receive EDP-938 or placebo. The cohort assessing food effect will enroll 10 subjects randomized to receive EDP-938 or placebo.

03

Conditions studied

  • RSV Infection

Keywords

  • First-in-Human
  • Single Ascending Dose
  • Multiple Ascending Dose
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • An document signed and dated by the subject.
  • Healthy male and female subjects of any ethnic origin between the ages of 18 and 55 years, inclusive.

Exclusion criteria

Exclusion Criteria:

  • evidence or history of illness or disease.
  • Pregnant or nursing females.
  • History of febrile illness within 7 days prior to the first dose of study drug or subjects with evidence of active infection.
  • A positive urine drug screen at screening or Day -1.
  • Current tobacco smokers or use of tobacco within 3 months prior to screening.
  • Any condition possibly affecting drug absorption (e.g., gastrectomy, cholecystectomy).
  • History of regular alcohol consumption.
  • Participation in a clinical trial within 30 days prior to the first dose of study drug.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    EDP-938 SAD Cohorts

    EDP-938 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5, and Dose 6 oral suspension, once daily in one single administration

    Drug: EDP-938

  • Experimental
    EDP-938 MAD Cohorts

    EDP-938 Dose 1, Dose 2, Dose 3, and Dose 4 oral suspension, once daily for 7 days

    Drug: EDP-938

  • Placebo comparator
    EDP-938 SAD Placebo Cohort

    Matching placebo, oral suspension, once daily in one single administration

    Drug: Placebo

  • Placebo comparator
    EDP-938 MAD Placebo Cohort

    Matching placebo, oral suspension, once daily for 7 days

    Drug: Placebo

Interventions

  • Subjects will receive either a single dose of EDP-938 on Day 1 only (SAD) or a single dose of EDP-938 starting on Day 1 through Day 7 (MAD).

  • DrugPlacebo

    placebo to match EDP-938

06

What researchers measure

Primary outcomes

  1. Safety measured by adverse events, physical exams, vital signs, 12-lead electrocardiograms (ECGs) and clinical lab results (including chemistry, hematology, and urinalysis).

    Time frame: Up to 8 days

Secondary outcomes

  1. Cmax of EDP-938

    Time frame: Up to 5 Days

  2. Cmax of EDP-938

    Time frame: Up to 11 Days

  3. AUC of EDP-938

    Time frame: Up to 5 Days

  4. AUC of EDP-938

    Time frame: Up to 11 Days

07

Study locations

1 site
  • Pharmaceutical Research Associates, Inc.,
    Lenexa, Kansas 66219, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Jul 2018, 6 months.

Of 44 industry-sponsored phase 1 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 6 months is close to that.

Counting every sponsor, half of 57 studies reached it within 8 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2017
First posted
Dec 27, 2017
StartActual
Dec 7, 2017
Primary completionActual
Jul 3, 2018
CompletionActual
Jul 3, 2018
Last update
Oct 10, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03384823
Collaborators
Pharmaceutical Research Associates
Responsible party
Sponsor
First posted
Dec 27, 2017
Start date
Dec 7, 2017
Primary completion
Jul 3, 2018
Completion
Jul 3, 2018
Last update
Oct 10, 2018

Study contacts

Enanta Pharmaceuticals, Inc
study director · Enanta Pharmaceuticals, Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EDP-938

Start the discussion